Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HRH2 | P25021 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.32 |
| ▸ | BACH1 | O14867 | 1/20 | 0.30 |
| ▸ | MAFK | O60675 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL301678 | 0.95 | — | — | |
| Carbimide SCHEMBL8927383 | 0.93 | CYP1A2 (0.54) | CYP1A2CYP2D6ALDH1A1HRH4TSHR | |
| Hydrochloric Acid SCHEMBL248532 | 0.93 | CYP1A2 (0.54) | CYP1A2CYP2D6ALDH1A1HRH4TSHR | |
| Ethane SCHEMBL8026831 | 0.93 | CYP1A2 (0.54) | CYP1A2CYP2D6ALDH1A1HRH4TSHR | |
| Hydrochloric Acid SCHEMBL28296907 | 0.91 | CYP1A2 (0.52) | CYP1A2CYP2D6ALDH1A1HRH4TSHR | |
| Iodomethane SCHEMBL7521844 | 0.91 | CYP1A2 (0.52) | CYP1A2CYP2D6ALDH1A1HRH4TSHR | |
| Ethane SCHEMBL2545448 | 0.91 | CYP1A2 (0.52) | CYP1A2CYP2D6ALDH1A1HRH4TSHR | |
| SCHEMBL27686663 | 0.89 | CYP1A2 (0.50) | CYP1A2CYP2D6ALDH1A1HRH4TSHR | |
| SCHEMBL3095991 | 0.88 | CYP1A2 (0.48) | CYP1A2CYP2D6ALDH1A1HRH4TSHR | |
| Ethyl Chloride SCHEMBL19668563 | 0.87 | CYP1A2 (0.53) | CYP1A2CYP2D6ALDH1A1HRH4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2679227-B1 | NANOPARTICLE CONTAINING PROSTAGLANDIN I2 DERIVATIVE | LTT BIO PHARMA CO LTD (JP) | 2018-04-11 | — | — | EP | disclosed |
| EP-1985309-B1 | NANOPARTICLES CONTAINING WATER-SOLUBLE NON-PEPTIDE LOW-MOLECULAR WEIGHT DRUG | LTT BIO PHARMA CO LTD (JP) | 2016-11-23 | — | — | EP | disclosed |
| US-9161986-B2 | Nanoparticle containing prostaglandin I2 derivative | LTT BIO-PHARMA CO., LTD. (JP) | 2015-10-20 | — | — | US | disclosed |
| US-8916206-B2 | Nanoparticles containing water-soluble non-peptide low-molecular weight drug | LTT BIO-PHARMA CO., LTD. (JP) | 2014-12-23 | — | — | US | disclosed |
| US-20140050690-A1 | NANOPARTICLE CONTAINING PROSTAGLANDIN I 2 DERIVATIVE | LTT BIO-PHARMA CO., LTD. (JP) | 2014-02-20 | — | — | US | disclosed |
| US-20110262548-A1 | NOVEL PROSTAGLANDIN E1 DERIVATIVE AND NANOPARTICLE HAVING THE SAME ENCAPSULATED THEREIN | LTT BIO-PHARMA CO., LTD. (JP) | 2011-10-27 | — | — | US | disclosed |
| EP-2361918-A1 | NOVEL PROSTAGLANDIN E1 DERIVATIVE, AND NANOPARTICLE HAVING SAME ENCAPSULATED THEREIN | LTT Bio-Pharma Co., Ltd. (JP) | 2011-08-31 | — | — | EP | disclosed |
| US-20100129456-A1 | SUSTAINED-RELEASE NANOPARTICLE CONTAINING LOW-MOLECULAR-WEIGHT DRUG WITH NEGATIVELY CHARGED GROUP | LTT BIO-PHARMA CO., LTD. (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-2156848-A1 | LOW-MOLECULE DRUG-CONTAINING NANOPARTICLE HAVING SUSTAINED RELEASE NEGATIVELY CHARGED GROUP | LTT Bio-Pharma Co., Ltd. (JP) | 2010-02-24 | — | — | EP | disclosed |
| US-20090317479-A1 | NANOPARTICLES CONTAINING WATER-SOLUBLE NON-PEPTIDE LOW-MOLECULAR WEIGHT DRUG | LTT BIO-PHARMA CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| EP-1985309-A1 | NANOPARTICLE CONTAINING WATER-SOLUBLE NON-PEPTIDIC LOW MOLECULAR WEIGHT SUBSTANCE | LTT Bio-Pharma Co., Ltd. (JP) | 2008-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110262548-A1 | NOVEL PROSTAGLANDIN E1 DERIVATIVE AND NANOPARTICLE HAVING THE SAME ENCAPSULATED THEREIN | PTGER1, PTGS1, PTGES | CYP1A2 938/4885CYP2D6 1148/4885ALDH1A1 62/4885 |
| US-20140050690-A1 | NANOPARTICLE CONTAINING PROSTAGLANDIN I 2 DERIVATIVE | PTGIS, PTGS2, PTGS1 | CYP1A2 1282/4885CYP2D6 2550/4885ALDH1A1 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.